Targeted Therapy for Metastatic Prostate Cancer
Name of the Trial
Why This Trial Is Important
Clinical trials have shown that chemotherapy with the drug docetaxel improves the survival of men with metastatic, androgen-independent prostate cancer. Currently, the combination of docetaxel and prednisone, a steroid drug, is approved by the FDA for treatment of androgen-independent prostate cancer.
This trial is evaluating the addition of two targeted therapies, bevacizumab and thalidomide, to chemotherapy with docetaxel and prednisone. Bevacizumab and thalidomide both interfere with the formation of new blood vessels in tumors, which is required for tumor growth and survival. These targeted therapies inhibit different cell-signaling pathways used by tumors to make new blood vessels and should, therefore, be more effective when given together than when either is given alone.
The preliminary results of this trial have been promising. "Of the 26 patients we've enrolled so far, only one patient has come off the trial for progression of disease," said Dr. Dahut. "The trial has been open for about a year, and the median survival of these patients with androgen-independent prostate cancer is about 15 months. That patients are still responding after a year is encouraging."
Who Can Join This Trial
Study Site and Contact Information
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.